Form 4: Cue Biopharma CFO Kerri-Ann Millar Granted Stock Options
SEC Form 4 Filing
Kerri-Ann Millar, CFO of Cue Biopharma, Inc., was granted stock options to purchase 200,000 shares of common stock on March 21, 2025.
Summary
- Kerri-Ann Millar, the Chief Financial Officer of Cue Biopharma, Inc., was granted stock options.
- The transaction occurred on March 21, 2025.
- The stock option allows Millar to purchase 200,000 shares of Cue Biopharma's common stock at an exercise price of $0.99 per share.
- The options vest in eight equal semi-annual installments starting on September 21, 2025.
- The options expire on March 20, 2035.
- Following the transaction, Millar directly owns 200,000 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.
Positives
- The granting of stock options to the CFO aligns her interests with those of the shareholders.
- The vesting schedule incentivizes long-term commitment from the CFO.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Biogen routinely grant stock options to their executives as part of their overall compensation strategy.
- The size of the grant (200,000 shares) would need to be compared to the total outstanding shares and the typical grant size for CFOs at comparable companies to determine if it is within industry norms.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the CFO to improve company performance.
- Employees may see this as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 03/21/2025 | Date of transaction: Stock options granted to Kerri-Ann Millar |
| 03/25/2025 | Date of Form 4 filing |
| 09/21/2025 | First vesting date for the stock options |
| 03/20/2035 | Expiration date of the stock options |
Keywords
stock options, CFO, Kerri-Ann Millar, Cue Biopharma, beneficial ownership, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.